Goldman Sachs Maintains Neutral on GeneDx Hldgs, Lowers Price Target to $8
Portfolio Pulse from Benzinga Newsdesk
Goldman Sachs analyst Matthew Sykes has maintained a Neutral rating on GeneDx Hldgs (NASDAQ:WGS) and lowered the price target from $9 to $8.
July 24, 2023 | 12:14 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Goldman Sachs has maintained a Neutral rating on GeneDx Hldgs and lowered the price target from $9 to $8.
The news directly pertains to GeneDx Hldgs as Goldman Sachs has maintained a Neutral rating on the company and lowered the price target. This could potentially impact investor sentiment and the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100